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Abstract
Background: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor
(VEGF) family. Over-expression of PlGF is known to be associated with pathological angiogenesis.
This study examined PlGF expression at protein and message levels in non-small cell lung cancer
(NSCLC), in which no reports on the significance of PlGF expression is available to date.
Patients and methods: We used immunohistochemistry to assess the PlGF protein and
correlated PlGF with microvessel density (MVD), as well as clinical outcome in patients with
NSCLC tumours (n = 91). In addition, we applied a real time quantitative PCR assay using SYBR
Green chemistry to measure PlGF mRNA in normal lung tissues and NSCLC tumours.
Results: PlGF was positively stained mainly in cytoplasm of lung cancer cells. High level staining of
PlGF was found in 38.5% NSCLC patients. A high level of MVD in NSCLC was found in 42.9% of
cases. Tumours with high level and low level PlGF staining had a significantly different MVD (26.69
vs. 20.79, respectively, p = 0.003). Using both univariate and multivariate analyses, PlGF was found
to be an independent prognostic factor. Real time PCR analysis revealed that PlGF mRNA was
higher in the cancer tissue than normal tissue (0.95 ± 0.19 vs. 0.57 ± 0.24; p < 0.005) and that PlGF
mRNA was significant higher in III-IV stage patients than in I-II stage patients (1.03 ± 0.20 vs. 0.80
± 0.17; p = 0.011).
Conclusion: PlGF expression is significantly more in NSCLC tumour tissues than in matched
normal tissues. It has a significant positive association with MVD and is an independent factor for
NSCLC patients. PlGF may have a pivotal role in NSCLC development and disease progression.
Introduction
Angiogenesis is essential for a solid tumour to grow
beyond 1–3 mm in diameter [1]. It also is a significant
predictive factor for prognosis in patients with solid
tumours [2,3]. Amongst the numerous angiogenic factors,
VEGF is the most powerful and most extensively studied.
VEGF belongs to a protein family, within which Placental
growth factor (PlGF) is a member (other members include
VEGF-B, -C and D). PlGF is a secreted, disulfide-linked
dimeric glycoprotein originally cloned from a cDNA
library of term placenta [4]. PlGF shares 53% of similarity
in its overall amino acid (aa) residues with VEGF. The bio-
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logical functions of VEGF and PlGF are similar, including
stimulation of the growth of vascular endothelial cells [5].
As a result of alternative splicing of the primary PlGF tran-
script, PlGF has at least three isoforms, PlGF-1 (PlGF149),
PlGF-2 (PlGF170) and PlGF-3 (PlGF221) [4]. In cells co-
expressing VEGF and PlGF mRNA, a heterodimeric VEGF/
PlGF protein has been detected [6,7]. VEGF/PlGF het-
erodimer has been shown to promote capillary growth in
vivo [7].
PlGF is known to specifically bind with Flt-1. VEGFR2/
KDR/Flk-1 and VEGFR1/Flt-1 are the two main receptors
of VEGF during the embryonic vascular development
[8,9]. Flk-1 primarily mediates VEGF signal transduction
and biological responses [10]. In addition to acting as the
receptor for VEGF and PlGF, Flt-1 is a special receptor for
VEGF-B. It has been shown that VEGF and PlGF can
induce transcription factors FosB and c-Fos mRNA expres-
sion, indicating the possibility that these factors may play
Table 1: The correlation between PlGF expression and the clinical pathological factors.
Variable Case(n and %) PlGF staining pattern P value (x2)
Low-staining (n =) High-staining (n =)
Sex
Male 63 (69.2%) 39 24 1.000
Female 28 (30.8%) 17 11
Age
≤60 43 (47.3%) 29 14 0.290
>60 48 (52.7%) 27 21
Histological type
Squamous carcinoma 42 (46.2%) 29 13 0.167
Adenocarcinoma 33 (36.3%) 20 13
Adenosquamous ca. 6 (6.6%) 3 3
Large cell carcinoma 2 (2.2%) 2 0
Carcinoid 2 (2.2%) 0 2
Alveolar carcinoma 6 (6.6%) 2 4
Grade of differentiation
Poor 11 (12.1%) 9 2 0.288
Moderate 48 (51.7%) 27 21
Well 32 (35.2%) 20 12
Tumour stage
T1 9 (9.9%) 7 2 0.643
T2 60 (65.9%) 37 23
T3 19 (20.9%) 10 9
T4 3 (3.3%) 2 1
Nodal status
N (-) 49 (53.8%) 31 18 0.829
N (+) 42 (46.2%) 25 17
Vessel cancer embolus
V (-) 67 (73.6%) 42 25 0.808
V (+) 24 (28.4%) 14 10
TNM stage
I 40 (43.9%) 28 12 0.173
II 20 (21.9%) 11 9
IIIa 28 (30.7%) 17 11
IIIb 1 (1.1%) 0 1
IV 2 (2.2%) 0 2World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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a role in the biological responses mediated by PlGF and
Flt-1 [9]. The protein and message for PlGF can be
detected in endothelial and epithelial cells and have been
found in a few tumours [7,10].
To our knowledge, there has been no report on the signif-
icance of PlGF expression with clinical outcome of
patients with lung cancer, including non-small cell lung
cancer (NSCLC). In order to ascertain the clinical signifi-
cance of PlGF expression in human non-small cell lung
cancer, we analysed the expression pattern of PlGF using
both immunohistochemical method and real time quan-
titative PCR and attempted to establish if a relationship
existed between PlGF and MVD, and subsequently
between PlGF and the predicted prognosis.
Patients and methods
Patients and samples
A total of 91 patients with non-small cell lung cancer, who
attended Beijing Cancer Hospital from July 2000 to
August 2003, were included. None of the patients received
any neoadjuvant therapy prior to operation. Histological
types of the lung cancer included squamous carcinoma,
adenocarcinoma, large cell carcinoma, squamous adeno-
carcinoma and alveolar carcinoma, pathologically (table
1). No other previous or concomitant primary cancer was
present. Clinico-pathological characteristics were defined
according to the TNM criteria of the UICC (11) (table 1).
Slides were reviewed and evaluated by two independent
researchers. Clinico-pathologic factors, such as age, sex,
histological types of tumours, tumour cell grade, TNM
stage, vessel embolism, lymph node metastasis, were
reviewed and stored in the patients' database. Patients
were followed up from the day of operation to August
2004 as the end of follow-up. The follow-up intervals
were calculated as survival intervals after surgery.
A separate collection of tissue samples from 21 primary
non-small cell lung cancers were used for mRNA based
analysis. These tumours were resected surgically from
patients at the Clinical Oncology School of Peking Uni-
versity from 2002 to 2003 and were saved in the Tissue
Bank of Peking University Oncology School. The patients
consisted of 13 men and 8 women, with a mean age of
56.2 ± 6.4 years. The histological type of lung cancer was
classified based according to the World Health Organiza-
tion classification [12]. Tumour staging was performed
according to the TNM staging criteria of the UICC [11].
The tumour specimens included 10 squamous cell carci-
nomas, 8 adenocarcinomas, and 3 undifferentiated carci-
nomas. Tumour staging was I in 3 cases, II in 7 cases, IIIA
or IIIB in 10 cases, and IV in 1 case. Immediately after sur-
gery, tumour samples and surrounding normal lung tis-
sues (more than 5 cm away from the tumour margin)
were placed in liquid nitrogen and stored frozen at -80°C
for RNA extraction and the RT-PCR.
Materials
The goat polyclonal antibody of PlGF and a mouse mon-
oclonal antibody of β-actin was purchased from Santa
Cruz Biotechnology (Santa Cruz, California, USA). The
mouse monoclonal antibody of CD31 was purchased
from Beijing Zhongshan Biotechnology Co. Ltd (Beijing,
China). The biotin conjugated anti-goat IgG, anti-mouse
IgG antibodies were purchased from Sigma (Poole, Dor-
set, England, UK). The Horse Radish Peroxidase (HRP)
conjugated anti-goat IgG, anti-mouse IgG antibodies were
obtained from Sigma (Poole, Dorset, England, UK). The
Target Retrieval Solution was purchased from DAKO
Corp. (Beijing, China). RNA extraction and reverse tran-
scription kits and PCR mix were purchased from Bio-Rad
Corp. (Beijing, China). Primers were synthesized by BioA-
sia Corporation (Shanghai, China). PCR reaction was car-
ried out using the iCycler iQ™ system (Bio-Rad). The
working stock solution of SYBR Green is 1:100 (Bio-Rad).
PlGF staining and microvessel counting
The paraffin-embedded tissue sections of 91 patients were
cut at 4 microns and mounted on polylysin-coated glass
slides for immunohistochemistry. Briefly, deparaffinized
sections were heated (60°C 1 hour). Antigen retrieval was
performed by heating the samples without boiling in Tar-
get Retrieval Solution (DAKO Corp.), pH 6.70 (200 ml) in
a microwave oven for 10 min. After endogenous peroxi-
dase was blocked with 3% hydrogen peroxide in the sec-
tion, each section was incubated with non-immunised
horse serum (Sigma) for 15 minutes, in order to block the
non-specific antigen site.
The immunohistochemical staining procedure was per-
formed according to the protocol of the DAKO Corp. The
primary anti-PlGF antibodies were used at a dilution
1:100 from the stock. The primary CD31 antibody was
used at working dilution of 1:100. The specificity of anti-
PlGF antibody was documented elsewhere [13].
Following incubation at 4°C overnight, the sections were
extensively washed and then incubated with link antibod-
ies (Sigma). Following more washing, bound antibodies
were linked to avidin-biotin-peroxidase according to
manufacturer's instruction (Dako Corp.). The staining
was completed by developing colour using the DAB
(diaminobenzidine tetrahydrochloride) solution for 5
min. The slides were counterstained with Mayers
Haematoxylin Blue in 0.3% ammonia. For negative con-
trols, sections were stained in the same manner, except
that the primary antibody was absent from the solution.
PlGF staining in lung cancer cells was independently
assessed by two observers using a modification of the sys-World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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tem of grading the relative intensity of immunoreactivity
for the respective antibodies [14]. PlGF immunohisto-
chemical staining of a tissue sample was graded as either
low level expression or high level. High-level staining rep-
resented uniformly intense immunoreactivity; low level
staining represented patchy and weak or negative
immunoreactivity.
MVD was evaluated as previously described [15]. After
screening the areas with intense neovasularized spots at
low power field (×100), microvessels in the area with the
highest number of discrete microvessels were counted in
a ×400 field. Three separate intense neovascularized areas
were assessed for each spot, and the mean was calculated
as MVD of each tumour evaluated. The MVD level were
graded as low level with MVD number lesser than 26,
while the high level with MVD number over than 26. This
was based on the pilot analysis of the microvessel density
according to pathological grade, in that 26 yielded a clear
division between the groups.
Generation of cDNA from NSCLC tissue and normal tissue 
and RT-PCR
RNA was extracted from tumour and the normal sur-
rounding tissues in RNA extraction buffer according to the
manufacturer's protocol. The concentration of RNA was
measured with a spectrophotometer. Reverse transcrip-
tion was performed from 1 µg of total RNA using oligo dt
primer according to the manufacture's instructions. Con-
ventional PCR primers were designed using Primer 3
http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi, to allow amplification of regions that
have no overlap with other known genes and span at least
one intron. Primers were synthesized by BioAsia Corpora-
tion (Shanghai, China): Primer sequences for PlGF were
5'ACGTGGAGCTGACGTTCTCT'3 and 5'CAGCAGGAGT-
CACTGAAGAG'3 and for GAPDH 5'AGGTCGGAGT-
CAACGGATTTG'3 and
5'GTGATGGCATGGACTGTGGT'3. Conventional PCR
was performed using cDNA from tissues together with the
PCR master mix using respective primers. The reaction
conditions were: 95°C 5 min, 94°C for 1 min, 55°C for
45 s, 72°C for 30 s and a final extension phase at 72°C for
7 min for 40 cycles. The PCR products were separated on
a 2% agarose gel and stained with 5 µl ethidium bromide
prior to examination under UV light and photographs
taken.
Generation of standard for real time PCR analysis
The PCR product from the above reaction was gel-excised
and purified using gel purification kit (Tianwei Corp, Bei-
jing). It was subsequently quantified on a gel with lambda
molecular weight standards and in a spectrophotometer.
The number of copies of target template was calculated.
The DNA sample was serially diluted to yield a concentra-
tion range between 102 to 108 copies, which was subse-
quently used as the internal standard. This was finally
prepared in elution buffer, aliquoted and stored at -80°C
until use.
Real Time quantitative RT-PCR
The iCycler iQ™ system incorporates a gradient thermocy-
cler and a 96-channel optical unit. SYBR Green as a DNA-
dye can affinity dsDNA was used to detect the PCR prod-
uct of PlGF and GAPDH. The melting point, optimal con-
ditions and the specificity of the reaction were first
determined using a standard procedure [17]. The working
stock solution of SYBR Green is 1:100 (Bio-Rad). Quanti-
tative PCR was carried out in 96-well plate with 10 pmol
forward and reverse primers, and the working solution
SYBR green, using a customer PCR master mix, with the
following conditions: 95°C for 5 minutes, followed by 40
cycles at 95°C for 1 minute, 55°C for 45 seconds, 72°C
for 30 second. Every assay included test cDNA samples,
10-fold serial dilutions of the standard qualification, and
controls (no template), as we previously reported [16].
The copy number of each transcript was calculated as the
relative copy number normalised by GAPDH copy
number.
Statistical analysis
Patients were divided into two groups: those with high-
level PlGF staining and those with low-level staining. Chi-
square analysis was used to test the association of PlGF
expression level with standard pathological variables.
Clinical pathological parameters and PlGF expression sta-
tus were correlated with survival time in both univariate
and multivariate analyses. Variables included in univari-
ate analysis were gender, TNM stage, grade of differentia-
tion, vessel cancer embolus, lymph nodal status and use
of postoperative adjuvant therapy, MVD and PlGF. Varia-
bles included in multivariate analysis were MVD, PlGF
expression status, gender, TNM stage, grade of differentia-
tion, vessel cancer embolus, lymphatic nodal status and
use of postoperative adjuvant therapy. The log-rank test
was used to test equality across categorical factors in
univariate analysis, and the level of significance was set at
p ≤ 0.05 based on two sided test. The multivariate analysis
was performed using Cox proportional hazards model,
and the level of significance was set at p ≤ 0.05 based on a
two sided test.
Paired-samples analysis was used (Student's t-test) to
determine whether the difference of PlGF mRNA expres-
sion level observed between matched cancer tissue and
the normal tissue. Independent-samples analysis was
used (Student's t-test) to determine whether the differ-
ences observed between PlGF expression level in NSCLC
tissue and the clinico-pathological characteristics. Statisti-World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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cal tests were performed using the software SPSS 10.0
(SPSS Inc., Chicago).
Results
Immunohistochemical analysis and the localization of 
PlGF in lung cancer
Lung cancer cells stained positively for PlGF. As shown in
figure 1A, 1B, adenocarcinoma cells showed strong and
diffuse cytoplasmic staining of PlGF. Squamous cancer
cells of the lung also displayed strong and positive cyto-
plasmic staining of PlGF as shown in figure 2A, 2B. Com-
pared with normal tissues of the lung as shown in figure
1E, 1F and 2E, 2F, the negative staining in tumour tissues
was shown in figure 1C, 1D and 2C, 2D.
PlGF and the clinical correlation
The immunohistochemical staining results of PlGF in
NSCLC were shown in table 1. High level expression of
PlGF in NSCLC was found in 35 (38.5%) cases. Among all
the available information, no significant correlation was
seen (p > 0.05).
Micro-vessel Density in lung cancer and its correlation with 
PlGF
The micro-vessel endothelial cells stained positively for
CD31. Endothelial cells showed strong and diffuse cyto-
plasmic staining of CD31, The correlation between MVD
and clinico-pathologic features in NSCLC were shown in
table 2. Low level of MVD in NSCLC was found in 52
(57.1%) cases. Amongst the available clinical parameters,
no clinical factors showed significant correlation with
CD31 as shown in table 2 (p > 0.05).
35 lung NSCLC tumours that had high-level expression of
PlGF had a mean MVD at 26.69 and the standard devia-
tion (SD) was 8.89. While in 56 NSCLS tumour which had
low-level staining of PlGF, the mean MVD ± SD was 20.79
± 8.82. The difference between the two groups was highly
significant, p = 0.003.
Clinical outcome and the prognostic value of variables
Univariate analysis of the impact of histological types and
PlGF expression status on prognosis was presented in
table 3. Longer survival time was found to be significantly
correlated with the following factors: low TNM stag (p =
0.0005), no lymph node metastasis (mean survival time,
41.04 months vs. 31.25 months, p = 0.0051), low level of
MVD (mean survival time, 39.96 months vs 31.85
months, p = 0.0434), and PlGF low-level expression
(mean survival time, 40.68 months vs 27.76 months, p =
0.0028).
A multivariate prognostic analysis based on the Cox pro-
portional hazard model was performed to test the inde-
pendent value of each parameter predicting overall
survival. Of the all the factors analysed (gender, tumour
TNM stage, grade of differentiation, vascular emboli of
cancer cells, nodal status and use of postoperative adju-
vant therapy, MVD level, and PlGF), TNM stage and high-
level PlGF were two independent prognostic factors,
which were the best general prognostic indicators (p =
0.007 and p = 0.011, respectively) (table 4). Furthermore
the relative risk of TNM stage and high-level PlGF expres-
sion were 1.311 and 2.738 respectively (95%CI, 1.076–
1.597 vs 1.269–6.102).
Figure 3A shows the Kaplan-Meier survival curve, based
on PlGF expression status. The cumulative survival time
for patients with PlGF low-expression (n = 56) was signif-
icantly longer than the patients with high-level PlGF (n =
35) (p = 0.0028). Figure 3B shows the Kaplan-Meier sur-
vival curve for 91 NSCLC patients based on lymphatic
node metastasis. The survival difference between lymph
node negative patients (n = 49) and positive patients (n =
42) was significant (P = 0.0051). Figure 3C shows the
Kaplan-Meier survival curve for 91 NSCLC patients based
on MVD status. The survival difference between low level
of MVD (n = 52) and high level MVD patients (n = 43)
was significant (p = 0.0434).
PlGF mRNA expression level in NSCLC and normal lung 
tissue assessed by real time RT-PCR
The amplification plot and the melting curve confirmed
that the amplification products for all three molecules
were specific (data not shown). We then employed the
analysis tool for both PlGF and GAPDH. The PlGF mRNA
(copy number of PlGF mRNA/copy number of GAPDH
mRNA) is shown here as the relative copy number. PlGF
mRNA expression and was detected in all 21 (100%)
paired lung cancer and non-tumorous lung tissue samples
by real time RT-PCR. The relative copy number for PlGF in
21 samples of lung cancer tissue ranged from 0.52 to 1.19,
with a mean ± standard deviation (SD) of 0.95 ± 0.20,
while the corresponding values in the matched non
tumours lung tissue ranged from 0.21 to 1.00, with a
mean ± SD of 0.57 ± 0.24. In 17 of 21 (81%) of patients,
tumours displayed higher PlGF than the matched normal
tissues. Only in 19% (4/21) of patients, healthy tissues
had higher levels than tumour tissues. PlGF mRNA expres-
sion in lung cancer tissue was significantly higher than in
the matched non tumorous lung tissue (95% CI:
0.2382~0.5321, p < 0.005, paired test).
Relationship between PlGF mRNA expression and 
clinicopathologic variables
Table 5 shows the relationship between PlGF mRNA
expression level and the clinico-pathological features.
PlGF mRNA was significantly higher in III-IV stage
patients than in stage I-II patients (1.03 ± 0.20 vs. 0.80 ±
0.17; p = 0.011, independent t  test). The differenceWorld Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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Immunohistochemical staining for PlGF in adenocarcinoma of lung Figure 1
Immunohistochemical staining for PlGF in adenocarcinoma of lung. A and B showed strong diffuse cytoplasmic staining of PlGF 
in adenocarcinoma of lung. C and D showed the negative staining of PlGF in adenocarinoma of lung. E and F showed the nega-
tive staining status of PlGF in normal alveolar (Original magnification is ×100).World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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Immunohistochemical staining for PlGF in squamous cell carcinoma of the lung Figure 2
Immunohistochemical staining for PlGF in squamous cell carcinoma of the lung. A and B showed strong diffuse cytoplasmic 
staining of PlGF in squamous carcinoma of the lung. C and D showed negative staining of PlGF in squamous carcinoma of lung. 
E and F showed the negative staining status of PlGF in alveolar. (Original magnification ×400)World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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between PlGF in different tumour size was not significant
(p > 0.05). The relationship between PlGF mRNA expres-
sion and sex, histological type, lymph node status was
otherwise not statistically significant.
Discussion
PlGF is a member of the VEGF family and is known to be
a powerful angiogenic factor, like its family members
VEGF. Although PlGF has been studies in a number of
clinical tumour types, little is known with regard to this
factor in lung cancer, particularly non-small cell lung can-
cer (NSCLC). The current study investigated the expres-
sion of PlGF, at the protein level and the messenger RNA
level and whether it had a bearing on clinical outcome in
patients with NSCLC.
Table 2: Microvessel Density counting vs. clinico-pathological features in the complete series (n = 91)
Variable Cases (n and %) MVD pattern P value (x2)
Low MVD (n =) High MVD (n =)
Sex
Male 63 (69.2%) 37 26 0.654
Female 28 (30.8%) 15 13
Age
≤60 43 (47.3%) 24 19 0.835
>60 48 (52.7%) 28 20
Histological type
Squamous carcinoma 42 (46.2%) 24 18 0.312
Adenocarcinoma 33 (36.3%) 20 13
Adenosquamous 
carcinoma
6 (6.6%) 2 4
Large cell carcinoma 2 (2.2%) 2 0
Carcinoid 2 (2.2%) 0 2
Alveolar carcinoma 6 (6.6%) 4 2
Grade of differentiation
Poor 11 (12.1%) 7 4 0.345
Moderate 48 (52.7%) 24 24
Well 32 (35.2%) 21 11
Tumour stage
T1 9 (9.9%) 5 4 0.988
T2 60 (65.9%) 34 26
T3 19 (20.9%) 11 8
T4 3 (3.3%) 2 1
Nodal status
N (-) 49 (53.8%) 29 20 0.678
N (+) 42 (46.2%) 23 19
Vessel cancer embolus
V (-) 67 (73.6%) 39 28 0.812
V (+) 24 (26.4%) 13 11
TNM stage
I 40 (44.0%) 27 13 0.389
II 20 (22.0%) 10 10
IIIa 28 (30.8%) 14 14
IIIb 1 (1.1%) 0 1
IV 2 (2.2%) 1 1World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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Firstly, the current study has demonstrated that PlGF can
be found, at the protein level and mRNA level, in lung
cancer cells. Furthermore, PlGF protein immunostaining
is primarily seen in the cytoplasmic region of the cells,
which is in accordance with literature reports. Stromal
Table 3: Potential prognostic factors using univariate analysis
Characteristics Patients (n =) Mean survival (mths) P Value*
Gender
Male 63 36.42 (31.77–41.08) 0.8860
Female 28 37.08 (30.73–43.44)
TNM stage
I 40 41.61 (37.35–45.87) 0.0005
II 20 38.44 (31.18–45.70)
IIIa 28 30.31 (22.76–37.86)
IIIb 1 6.00 (6.00-6.00)
IV 2 13.50 (3.11–23.89)
Grade of differentiation
Well 32 37.43 (31.17–43.69) 0.4984
Moderate 48 34.76 (29.86–39.67)
Poor 11 39.73 (28.34–51.12)
Nodal status
N (-) 49 41.04 (36.64–45.45) 0.0051
N (+) 42 31.25 (25.64–36.86)
Vessel cancer embolus
V (-) 67 37.50 (33.41–41.58)
V (+) 24 33.89 (25.75–42.03)
Postoperative adjuvant 
therapy
No 26 37.47 (29.70–45.24) 0.7225
Chemotherapy or Radiation 65 36.03 (31.57–40.49)
MVD
High MVD 39 31.85 (25.68–38.03) 0.0434
Low MVD 52 39.96 (35.48–44.44)
PlGF staining
Low expression 56 40.68 (36.70–44.66) 0.0028
Over expression 35 27.76 (21.17–34.34)
* Log-Rank Test
Table 4: The prognostic value of PlGF staining evaluated on the basis of multivariate analysis in the COX model (Backward: Wald) for 
91 NSCLC cases.
Variable Regression 
Coeff. (B)
Standard error 
(SE)
Wald value P value OR (EXP) 95% CI for OR
PlGF expression 1.024 0.401 6.532 0.011 2.738 (1.269–6.102)
TNM staging 0.271 0.101 7.201 0.007 1.311 (1.076–1.597)World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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cells and endothelial cells displayed little staining. Sec-
ondly, PlGF is significantly linked to MVD. High levels of
PlGF are significantly linked to high MVD.
The angiogenic role of PlGF is interesting to observe. PlGF
expression is restricted to the placenta tissue in normal
physiological condition [18] and has been indicated to
play an important role in the angiogenic process. There is
Overall survival of NSCLC patients based on PlGF (left), nodal status (middle) and MVD (right) Figure 3
Overall survival of NSCLC patients based on PlGF (left), nodal status (middle) and MVD (right). Left: PlGF and the overall sur-
vival. A, PlGF low expression tumours (n = 56). B, PlGF over expression tumours (n = 35). The survival curves are significantly 
separated and the patients with PlGF low expression have long survival time than those with over expression (p = 0.0028, log-
rank test). Middle: Overall survival based on nodal status of NSCLC patients (n = 91). The difference between nodal negative 
patients (A, n = 49) and nodal positive patients (B, n = 42) is significant (p = 0.0051, log-rank test). Right: Overall survival based 
on MVD status of NSCLC patients (n = 91). The difference between low level of MVD (A, n = 52) and high level MVD patients 
(B, n = 43) is significant (p = 0.0434, log-rank test).
Table 5: Relationship between relative levels of PlGF mRNA (PlGF/G3PDH) and clinico-pathologic characteristics
Variables No. PlGF mRNAa (mean ± SD) P value
Sex
Male 13 0.8760 ± 0.2468 0.261
Female 8 0.9881 ± 0.1461
Histologic type
Squamous 10 0.9706 ± 0.2153 0.307
Non squamous 11 0.8714 ± 0.2177
Stage
I–II 10 0.7979 ± 0.1744 0.011
III–IV 11 1.0284 ± 0.1977
Tumour status
T1 6 0.7939 ± 0.1656 0.096
T2–4 15 0.9686 ± 0.2195
Lymph node status
N0 8 0.8231 ± 0.1640 0.116
N1–3 13 0.9775 ± 0.2303
Tissue
Tumour 21 0.9187 ± 0.2171 <0.005*
Adjacent normal tissue 21 0.5652 ± 0.2406
aPlGF mRNA expression derived from real-time quantitative RT-PCR: PlGF/GAPDH.
*p value derived from paired t test; others derived from independent t test.World Journal of Surgical Oncology 2005, 3:68 http://www.wjso.com/content/3/1/68
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evidence to suggest that up-regulation of PlGF and
VEGFR-1 expression can stimulate the response of vascu-
lar endothelial cells to VEGF and enhance angiogenesis in
pathological disorders [19]. Although the precise mecha-
nism by which PlGF regulates angiogenesis is unclear,
some leads have been suggested. Up-regulation of PlGF
can displace VEGF from Flt-1 and will make more VEGF to
bind and activate Flk-1 [20]. PlGF activates Flt-1 and will
lead to intermolecular transphosphorylation of Flk-1.
This can enhance phosphorylation levels of Flk-1 on tyro-
sine residues. Furthermore, VEGF/PlGF heterodimer can
activate and transmit angiogenic signals through the Flk-
1/Flt-1 heterodimer receptor complex.
In the current study, a high level of PlGF was seen 38.46%
of all the cases. The significant correlation between PlGF
and MVD further indicates that PlGF expression level is
associated with MVD, and potentially with angiogenesis
in human lung cancer. We, and others, have previously
reported that MVD was an influence factor to predict the
prognosis of patients with non-small cell lung cancer Fur-
thermore, both univariate and multivariate analyses
revealed that PlGF is an independent prognostic factor.
Taken together, it is concluded that PlGF is an important
factor that can influence the angiogenesis process in
NSCLC, and that the levels of PlGF reflect MVD, which
might be a predictive factor for NSCLC patients'
prognosis.
The current study has used quantitative real time PCR, to
determine the levels of PlGF gene transcript. It has been
shown that PlGF mRNA expression was detected in all
NSCLC tissues and the matched normal tissues. The levels
of PlGF transcript in these tissues varied from weak to
strong. In 17 pairs of lung cancer and normal tissue sam-
ples, PlGF mRNA expression level in cancers was signifi-
cant higher than the normal tissue. There has been no
report about the PlGF mRNA expression level in NSCLC,
although limited reports have studied mRNA expression
of VEGF, a family member of PlGF, in NSCLC. Dolrini et
al reported VEGF mRNA expression in cancer and normal
tissue samples from 22 patients with the method of quan-
titative competitive real time PCR [21]. They detected
VEGF mRNA in 18 samples of healthy tissue and all sam-
ples of tumour tissue and found that VEGF expression was
higher in the tumour tissue than in the matched healthy
tissue in 17 cases [21]. The current study has also sup-
ported by a recent report to show that lung cancer cell
lines expressed PlGF, although it was indicated that SCLC
tissues had a higher levels of PlGF staining than NSCLC
[22]. Collectively, we suggest that PlGF is a factor that has
strong prognostic value in NSCLC as shown in the present
study and possibly in SCLC as shown in a smaller scale
study [22]. A larger scale study will undoubtedly further
clarify the connection.
The other interesting finding from the current study is that
PlGF mRNA expression level has no significant difference
with sex, histological type, tumour size, and lymph node
status. However, advanced NSCLC tumours (stage III-IV)
have higher levels of PlGF expression than the early stage
NSCLC (I-II). This is somewhat in contrast with the
immunohistochemical assessment, in that little statistical
difference was observed between different stages (table 1).
This is interesting and perhaps reflects the following: (1)
the sensitivity of different assays. Quantitative analysis of
gene transcript is a highly sensitive technique which can
detect minute amount of genetic material. The technique
also allows detection of very high levels of expression.
Immunohistochemical analysis and the assessment based
on colorimetric staining are less sensitive and sometime
subjective in nature. (2) The correlation between protein
and mRNA. Although a good relationship between mRNA
and protein translation in the cells have been well docu-
mented, this may not be exactly translated at the tissue
level. Thus, each technique has its advantage, i.e. Q-PCR
for sensitivity and quantitative nature and IHC for its abil-
ity to identify protein and the location of proteins.
In summary, the current study has shown that the ang-
iogenic factor, PlGF is ubiquitously in lung tissues and is
predominantly a cytoplasmic protein in lung epithelial
and lung cancer cells. PlGF expression is significantly
higher in cancer tissue than in normal tissue, and is posi-
tively correlated with tumour stage and tumour size. This
indicates that PlGF may have some role in tumour pro-
gression and that blocking/targeting PlGF expression may
have promising therapeutic future in NSCLC.
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